Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Los Angeles › NPI 1336279959
Hospital

County of Los Angeles

County of Los Angeles was paid $8.79M by Medicaid between Jan 2018 and Sep 2024, across 202 billing codes. Its largest line is 0111, — 39% of everything it billed.

33Billing provider infoCOUNTY OF LOS ANGELES
LOS ANGELES, CA 90033
33aNPI1336279959assigned 03/06/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.79M
24GClaims279,717
24DCodes billed202
24AFirst – last monthJan 2018 – Sep 2024
Compared with peers

Next to other General Acute Care Hospital providers in California

Rank by total paid#194 of 410
Median peer was paid$6.90M
This provider vs. median1.3×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$250K$500K$750K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018151,120$2.67M
201981,940$1.99M
20209,070$131K
202112,485$1.83M
202211,663$1.66M
202312,366$486K
2024incomplete1,073$15K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
0111 39% 307 289 $3.40M
0450 Emergency room services 15% 32,960 28,794 $1.32M
G0463 Hospital outpatient clinic visit for assessment and management of a patient 4.4% 12,726 10,490 $390K
74174 4.0% 1,641 1,510 $356K
99205 Prolong outpt/office vis 3.4% 2,289 1,973 $303K
70450 Computed tomography, head or brain; without contrast material 3.0% 2,916 2,684 $260K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 2.1% 10,298 8,734 $188K
0200 2.1% 15 13 $187K
99281 Emergency department visit for the evaluation and management, self-limited or minor 2.1% 10,032 8,408 $185K
G0378 Hospital observation service, per hour 1.9% 809 458 $164K
99215 Doctor's office visit, returning patient (complex)Prolong outpt/office vis 1.8% 1,185 957 $161K
72125 Computed tomography, cervical spine; without contrast material 1.4% 965 904 $125K
190 more codes
99282 Emergency department visit for the evaluation and management, low to moderate severity 1.2% 6,495 $110K
0510 1.2% 4,486 $101K
71260 Computed tomography, thorax, diagnostic; with contrast material 1.1% 589 $93K
99283 Emergency room visit (moderate) <1% 2,051 $75K
0250 <1% 23,330 $69K
80048 Basic metabolic panel (calcium, ionized) <1% 11,907 $66K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 13,285 $65K
99199 Unlisted special service, procedure or report <1% 877 $60K
71046 Radiologic examination, chest; 2 views <1% 3,534 $48K
70486 <1% 377 $42K
71045 Radiologic examination, chest; single view <1% 5,926 $42K
J7030 Infusion, normal saline solution , 1000 cc <1% 6,419 $39K
80076 <1% 7,581 $38K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 3,386 $36K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 1,585 $34K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 1,513 $33K
84484 <1% 4,177 $30K
99221 <1% 3,299 $28K
J1953 Injection, levetiracetam, 10 mg <1% 120 $27K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 1,886 $27K
83690 <1% 5,285 $22K
80053 Comprehensive metabolic panel <1% 2,580 $19K
83605 <1% 2,515 $19K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 319 $18K
83880 <1% 1,043 $17K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 435 $17K
73564 <1% 762 $17K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 292 $15K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 305 $15K
73610 <1% 785 $15K
85610 <1% 5,763 $15K
93971 <1% 213 $14K
73110 <1% 658 $12K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 2,102 $11K
73030 <1% 569 $11K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 500 $11K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 459 $11K
86703 <1% 1,373 $11K
80047 <1% 2,028 $11K
73080 <1% 475 $10K
73590 <1% 608 $10K
87040 <1% 805 $9K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 931 $9K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 510 $9K
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 1,777 $9K
73090 <1% 552 $9K
86850 <1% 2,429 $9K
80306 <1% 360 $8K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 253 $8K
87522 Neg quan hep c or qual rna <1% 345 $8K
76801 <1% 184 $8K
99284 Emergency room visit (serious) <1% 220 $8K
82550 <1% 1,548 $8K
87088 <1% 1,963 $7K
73130 <1% 411 $7K
74177 Computed tomography, abdomen and pelvis; with contrast material <1% 178 $7K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 671 $7K
99217 <1% 47 $7K
86901 <1% 2,602 $6K
73630 <1% 378 $6K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 275 $6K
81000 <1% 3,191 $6K
0255 <1% 107 $6K
Q0144 Azithromycin dihydrate, oral, capsules/powder, 1 gram <1% 358 $6K
81025 <1% 2,033 $6K
81001 <1% 3,072 $6K
0761 <1% 470 $5K
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 363 $5K
0516 <1% 188 $5K
73120 <1% 410 $5K
86900 <1% 2,591 $5K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 516 $5K
73620 <1% 395 $5K
99218 <1% 84 $5K
86141 <1% 771 $5K
85730 <1% 1,271 $5K
84703 <1% 1,043 $5K
94760 <1% 615 $5K
J0780 Injection, prochlorperazine, up to 10 mg <1% 412 $5K
J1630 Injection, haloperidol, up to 5 mg <1% 1,027 $5K
71275 Computed tomographic angiography, chest, with contrast material <1% 30 $4K
0760 <1% 289 $4K
J2060 Injection, lorazepam, 2 mg <1% 882 $4K
70498 <1% 25 $4K
J7120 Ringers lactate infusion, up to 1000 cc <1% 636 $4K
83036 Hemoglobin; glycosylated (A1C) <1% 602 $3K
93010 Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only <1% 597 $3K
85027 <1% 808 $3K
36415 Collection of venous blood by venipuncture <1% 10,419 $3K
J1170 Injection, hydromorphone, up to 4 mg <1% 540 $3K
80061 Lipid panel <1% 357 $3K
S0077 Injection, clindamycin phosphate, 300 mg <1% 137 $3K
80305 <1% 489 $3K
72100 <1% 142 $3K
81015 <1% 1,445 $3K
87070 <1% 485 $3K
J8540 Dexamethasone, oral, 0.25 mg <1% 216 $3K
87210 <1% 869 $3K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 104 $2K
J2270 Injection, morphine sulfate, up to 10 mg <1% 583 $2K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 595 $2K
73060 <1% 146 $2K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 628 $2K
72170 <1% 153 $2K
92012 Ophthalmological services: medical examination and evaluation, intermediate, established patient <1% 76 $2K
87536 <1% 62 $2K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 137 $2K
87186 <1% 396 $2K
82962 <1% 1,279 $2K
93041 <1% 273 $2K
J3475 Injection, magnesium sulfate, per 500 mg <1% 197 $2K
73502 <1% 84 $2K
97161 <1% 73 $2K
81002 <1% 1,286 $2K
77067 Screening mammography, bilateral, including computer-aided detection <1% 29 $2K
J7644 Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram <1% 704 $2K
73552 <1% 96 $2K
83026 <1% 872 $2K
J7050 Infusion, normal saline solution, 250 cc <1% 731 $1K
83735 <1% 303 $1K
90999 Dialysis (unlisted procedure) <1% 62 $1K
82140 <1% 184 $1K
86592 <1% 502 $1K
73562 <1% 53 $1K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 359 $1K
Q0163 Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen <1% 687 $1K
76870 <1% 33 $1K
84439 <1% 212 $1K
88182 <1% 39 $1K
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 236 $941.66
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 155 $895.33
84100 <1% 282 $889.17
87340 <1% 179 $881.94
J1940 Injection, furosemide, up to 20 mg <1% 117 $832.55
90792 Psychiatric diagnostic evaluation with medical services <1% 14 $758.69
59025 Fetal non-stress test <1% 16 $755.70
J3370 Injection, vancomycin hcl, 500 mg <1% 72 $737.45
99222 Initial hospital care, per day, moderate complexity <1% 13 $724.70
85378 <1% 155 $724.50
J7510 Prednisolone oral, per 5 mg <1% 168 $715.30
86593 <1% 314 $706.92
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 13 $681.40
86480 <1% 25 $665.93
87086 Culture, bacterial; quantitative colony count, urine <1% 158 $661.75
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 97 $656.94
99213 Doctor's office visit, returning patient (routine) <1% 87 $648.07
76770 <1% 14 $595.74
84702 <1% 56 $562.44
J7611 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg <1% 477 $547.90
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 14 $488.97
85007 <1% 264 $436.44
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 102 $414.26
80185 <1% 86 $398.73
88142 <1% 100 $377.89
84145 <1% 26 $361.79
0320 <1% 126 $357.57
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 124 $341.33
82274 <1% 28 $335.51
93000 <1% 13 $321.67
87205 <1% 115 $277.57
J7060 5% dextrose/water (500 ml = 1 unit) <1% 92 $232.25
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 654 $231.30
S0028 Injection, famotidine, 20 mg <1% 264 $214.80
73501 <1% 14 $200.74
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 18 $171.16
80320 <1% 493 $170.54
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 42 $163.96
84443 Thyroid stimulating hormone (TSH) <1% 12 $161.00
85652 <1% 85 $155.32
98960 <1% 89 $152.20
74018 <1% 13 $149.73
73140 <1% 13 $143.35
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 31 $139.38
0300 <1% 28 $114.17
88187 <1% 16 $111.96
81003 <1% 103 $92.48
82043 <1% 16 $89.21
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 15 $66.35
86780 <1% 13 $66.12
82540 <1% 16 $62.75
G0008 Administration of influenza virus vaccine <1% 12 $53.06
A4216 Sterile water, saline and/or dextrose, diluent/flush, 10 ml <1% 53 $51.03
80329 <1% 517 $49.98
S5550 Insulin, rapid onset, 5 units <1% 59 $48.22
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 16 $23.62
96415 <1% 15 $22.88
89050 <1% 23 $18.88
85008 <1% 15 $9.03
92557 <1% 25 $1.98
91300 0% 12 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialOROZCO, JORGE (CHIEF EXECUTIVE OFFICER)
Same official

Other billing entities under OROZCO, JORGE

Full network →
ProviderLocationPaid
County of Los AngelesLos Angeles, CA$216.55M
County of Los AngelesLos Angeles, CA$63.83M
County of Los AngelesLos Angeles, CA$19.75M
County of Los AngelesLos Angeles, CA$1.24M
County of Los AngelesLos Angeles, CA$306K
County of Los AngelesLos Angeles, CA$26K
County of Los AngelesLos Angeles, CA$2K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.